Related Experiment Videos
Clinical safety of flurbiprofen
C D Brooks1, O I Linet, D Schellenberg
1Pharmaceutical Research Division, Upjohn Company, Kalamazoo, Michigan 49001.
Journal of Clinical Pharmacology
|April 1, 1990
Summary
Flurbiprofen, a nonsteroidal anti-inflammatory drug (NSAID), shows a lower incidence of serious upper gastrointestinal and urinary tract adverse drug reactions (ADRs) compared to aspirin. Clinical safety data indicate flurbiprofen is well-tolerated for NSAID therapy.
Area of Science:
- Pharmacology
- Clinical Medicine
- Drug Safety
Background:
- Nonsteroidal anti-inflammatory drugs (NSAIDs) are widely used for pain and inflammation.
- Understanding the safety profile of NSAIDs, including flurbiprofen, is crucial for patient care.
- Comparative safety data between NSAIDs and aspirin are essential for clinical decision-making.
Purpose of the Study:
- To analyze adverse drug reactions (ADRs) associated with flurbiprofen.
- To compare the safety of flurbiprofen with aspirin and placebo.
- To evaluate the overall tolerability of flurbiprofen in patients with painful musculoskeletal conditions.
Main Methods:
- Pooled analysis of data from 58 premarketing studies.
- Inclusion of 5602 patients treated with flurbiprofen, aspirin, or placebo.
- Review of additional studies and published reports on flurbiprofen safety.
Main Results:
- Flurbiprofen demonstrated a lower rate of serious upper gastrointestinal ADRs than aspirin.
- Serious urinary tract ADRs were less frequent with flurbiprofen compared to aspirin.
- No serious hemic/lymphatic system ADRs were observed in the flurbiprofen group; hematocrit decrease was less common than with aspirin.
Conclusions:
- Flurbiprofen is a well-tolerated NSAID at the studied doses.
- The safety profile of flurbiprofen is favorable, particularly regarding gastrointestinal and urinary tract adverse events.
- Clinical safety data support the use of flurbiprofen for patients requiring NSAID therapy.